论文部分内容阅读
AIM: To examine the effect of eradication of Hellcobacter pylori prior to usage of NSAIDs, by investigating gastric inflammatory activity, myeloperoxidase (MPO) activity, prostaglandin (PG) E_2 synthesis in H Pylori-infected, and H pylori-eradicated gerbils followed by administration of indomethacin and rofecoxib. METHODS: Six-week-old male gerbils were orally inoculated with H pylori. Seven weeks later, anti-H pylori triple therapy and vehicle were given to gerbils respectively and followed by oral indomethacin (2 mg/kg·d) or rofecoxib (10 mg/kg·d) for 2 wk. We examined the area of lesions, gastric inflammatory activity, PGE_2 synthesis and MPO activity in the stomach. RESULTS: In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm~2): 82.4±9.2 vs 13.9±3.5 (P＜0.05), 30.5±5.1 vs 1.3±0.6 (P＜0.05); erosion and ulcer area (mm~2): 14.4±4.9 vs 0.86±0.5 (P＜0.05), 1.3±0.6 vs0.4±0.3 (P＜0.05); score of gastritis: 7.0±0.0 vs3.6±0.5 (P＜0.05), 7.0±0.0 vs 2.7±0.5 (P＜0.05); MPO activity (μmol H_2O_2/min/g tissue): 104.7±9.2 vs9.0±2.3(P＜0.05), 133.5±15.0 vs2.9±0.7 (P＜0.05); PGE_2 synthesis (pg/mg wet weight/min): 299.2±81.5 vs102.8±26.2 (P＜0.05), 321.4±30.3 vs 11.9±4.8(P＜0.05). CONCLUSION: Eradication of H pylori reduced gastric damage of NSAID-treated Mongolian gerbils. Rofecoxib caused less severe gastric damage than indomethacin in H pylori-eradicated gerbils.
AIM: To examine the effect of eradication of Hellcobacter pylori prior to usage of NSAIDs, by investigating gastric inflammatory activity, myeloperoxidase (MPO) activity, prostaglandin (PG) E_2 synthesis in H Pylori-infected, and H pylori-eradicated gerbils followed by administration of indomethacin and rofecoxib. METHODS: Six-week-old male gerbils were orally inoculated with H pylori. Seven weeks later, anti-H pylori triple therapy and vehicle were given to gerbils respectively followed by oral indomethacin (2 mg / kg.d ) or rofecoxib (10 mg / kg · d) for 2 weeks. We examined the area of lesions, gastric inflammatory activity, PGE 2 synthesis and MPO activity in the stomach. RESULTS: In indomethacin and rofecoxib-treated gerbils, the following results were in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm 2): 82.4 ± 9.2 vs 13.9 ± 3.5 (P <0.05), 30.5 ± 5.1 vs 1.3 ± 0.6 (P <0.05) ; erosion and ulcer area (mm ~ 2): 14.4 ± 4.9 vs 0.86 ± 0.5 (P <0.05), 1.3 ± 0.6 vs 0.4 ± 0.3 (P <0.05); score of gastritis: 7.0 ± 0.0 vs 3.6 ± 0.5 (P < 0.05); MPO activity (μmol H 2 O 2 / min / g tissue): 104.7 ± 9.2 vs 9.0 ± 2.3 (P <0.05), 133.5 ± 15.0 vs 2.9 ± 0.7 weight loss): 299.2 ± 81.5 vs 102.8 ± 26.2 (P <0.05), 321.4 ± 30.3 vs 11.9 ± 4.8 (P <0.05). CONCLUSION: Eradication of H pylori reduced gastric damage of NSAID- treated Mongolian gerbils. Rofecoxib caused less severe gastric damage than indomethacin in H pylori-eradicated gerbils.